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Abstract 
Thalidomide and its derivatives are immunomodulatory drugs (IMiDs) known for their 
sedative, teratogenic, anti-angiogenic, and anti-inflammatory properties. Commonly used in 
the treatment of cancers such as Multiple Myeloma and Myelodysplastic Syndrome, IMiDs 
have also been used in the treatment of an inflammatory skin pathology associated with 
Hansen’s disease/Leprosy and show promise in the treatment of autoimmune disorders 
including Systemic Lupus Erythmatosus and Inflammatory Bowel Disease. Recent 
structural and experimental observations have revolutionized our understanding of these 
properties by revealing the fundamental molecular events underpinning IMiD activity. Here, 
we review these findings, their relevance to IMiD therapy in immunological disorders, and 
discuss how further research might unlock the vast clinical potential of these compounds. 
Evolving Interest in the Thalidomide Mechanism of Action 
Thalidomide remains best known as the cause of congenital limb abnormalities in what is 
considered by many to be the greatest medical scandal of the last century. In 1957 and 
marketed by the German pharmaceutical company Chemie-Grunenthal, thalidomide, under 
the trade-name Contergan, was introduced to the world as a completely non-toxic sedative 
that could be used safely, even during pregnancy [1]. Prescribed to alleviate morning sickness, 
it was widely distributed with tragic consequences; until its discontinuation in 1961, up to 
10,000 babies were born with characteristic limb defects, referred to as phocomelia, with 
estimations rising to up to 100,000 if premature births and miscarriages were included [1-3]. 
According to The Thalidomide Trust, in the UK alone up to 467 individuals continue to live 
with consequences of the inadequate testing and regulatory regime governing drug 
distribution at that time. Worldwide, the figure could be as many as 3000 [4].  
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Over 55 years since its discontinuation controversy surrounding compensation for those 
affected continues to be a subject of media interest [1, 2, 4]. Recent decades have seen a more 
positive side to thalidomide emerge. It was first introduced as an anti-inflammatory therapy 
with remarkable efficacy in the treatment of Erythema Nodosum Leprosum (ENL),[5] an 
inflammatory condition associated with leprosy, and later, in the treatment of Multiple 
Myeloma [6]. Recognition of thalidomide’s therapeutic value led to renewed interest and the 
development of thalidomide derivatives with enhanced potency, most notably lenalidomide. 
These next generation thalidomide derivatives, developed by the pharmaceutical company 
Celgene and collectively referred to as IMiDs, have received approval or are in development 
for the treatment of cancers including Mantle Cell Lymphoma, Acute Myeloid Leukemia, 
and hepatocellular carcinoma (HPC),  in addition to autoimmune disorders such as 
psoriasis, Systemic Lupus Erythmatosus (SLE) and Inflammatory Bowel Disease (IBD) 
(Table 1).  
Unusually, IMiDs have achieved widespread use in the absence of a clear mechanistic 
understanding of their properties. Indeed, the precise molecular target of thalidomide has 
until recently remained unclear. Pioneering biochemical work using thalidomide conjugated 
beads enabled the seminal discovery that Cereblon, a substrate adaptor in the Cullin4A 
(CUL4A) ubiquitin ligase complex,[7] is a receptor for these compounds and responsible 
thalidomide teratogenicity [8]. Interest following this discovery prompted a series of studies, 
mostly using in vitro cell lines, that have defined key molecular processes underlying IMiD 
therapy in Multiple Myeloma and a subset of Mylodysplastic Syndrome subjects haboring a 
deletion in the long arm of chromosome 5 (MDS del (5q)). To date, however, few studies 
have addressed the implications of these findings when considering the anti-inflammatory 
properties of IMiDs. Indeed, recent advances in our understanding of the IMiD mechanism of 
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action have seldom been considered from an immunological perspective. Here, by discussing 
potential mechanisms underlying IMiD therapy in immunological disorders, we aim to 
encourage discussion on this comparatively neglected aspect of IMiD research.  
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The Anti-inflammatory Properties of Thalidomide: Use in Hansen’s Disease/Leprosy 
The story of thalidomide’s anti-inflammatory properties begins with a single case report 
published not long after thalidomide’s market withdrawal; a patient suffering from Hansen’s 
disease, commonly known as Leprosy, and taking thalidomide for its sedative properties, 
observed the complete resolution of inflammatory skin lesions associated with this condition 
[5]. 
The result of infection with Mycobacterium Leprae, Leprosy is initially a disease of the 
Peripheral Nervous System (PNS). Infection first occurs in Schwann cells, [9] a neuronal 
cell lineage responsible for synthesis of the Myelin Sheath.  The resulting neuronal damage 
causes a loss of sensory function [9]. Schwann cell migration then facilitates the spread of 
infection to other tissues triggering a T helper 1 (Th1) type immune response [9, 10]. In 
many cases the infection is effectively contained and in some cases resolved, resulting in a 
mild form of disease termed Tuberculoid Leprosy [11]. However, in susceptible individuals, 
anergic T-cell responses permit further bacterial infiltration and the development of 
Lepramatous Leprosy, an extensive infection frequently accompanied (Approximately 50% 
of patients) by the development of painful skin lesions covering the whole body [10-12]. This 
dermatological condition, termed Erythema Nodosum Leprosum (ENL), is the result of  
immune reactions to M. Leprae and constitutes a major cause of morbidity in Leprosy [11]. 
Treatment options for ENL involve administration of either Clofazimine or thalidomide, and 
although there is some disagreement over which is the more appropriate,[11, 13] the efficacy 
of thalidomide is typically described as exceptional, with an estimated 70-90% of patients 
responsive to therapy and many exhibiting a rapid and complete recovery in a matter of days 
following treatment onset [11, 14].  
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Studies addressing the mechanism underlying these properties have typically focused on 
thalidomide’s effect on the cytokine milieu. Initial studies of in vitro stimulated human 
monocytes revealed a suppressive effect of thalidomide on the pro-inflammatory cytokine 
TNFα induced via the Lipopolysaccharide (LPS) receptor, Toll-like receptor 4 (TLR4) [15, 
16]. The production of other cytokines, including IL12,[17] and in our hands, IL6 and IFN-ȕ, 
[18] were also suppressed in thalidomide treated, LPS stimulated human monocytes and 
murine peritoneal macrophages, respectively.  
While there is no direct evidence linking this pathway to ENL pathogenesis, TLR induced 
immune responses form an essential part of the host response to intracellular bacteria and are 
likely to be active in patients with Leprosy. For example, a study of Mycobacterium 
Tuberculosis, which is highly similar to M. Leprae, revealed that the induction of pro-
inflammatory cytokines IL6, TNFα and IL1βp40 in response to infection was dependent on 
both Toll-like receptor 2 and 9 (TLR2/TLR9) in vitro [19]. This type of pro-inflammatory 
response can in turn drive theTh1 responses that are characteristic of infection with 
Mycobacteria [19]. Indeed, Tlr2-/-/Tlr9-/- double knockout mice fail to exhibit hallmarks of a 
Th1-type immune response, such as increased serum IFN-Ȗ, in response to infection with M. 
Tuberculosis [19]. In a separate study, the activation of Toll-like receptor 7 (TLR7) by 
phagocytised bacteria was seen to provoke type-1 interferon production by conventional 
dentritic cells stimulated in vitro [20]. This likely provides a strong protective affect as Tlr7-/- 
mice exhibit decreased survival during bacterial infection, in this case with B Streptococcus 
[20]. Thus, we consider that cytokine and type-1 interferon production induced via TLRs 2, 7, 
and 9 may potentially mediate host responses to M. Leprae and be implicated in the 
pathogenesis of ENL. 
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Circumstantial evidence is supportive of this hypothesis. For instance, peripheral blood 
mononuclear cells (PBMC) isolated from ENL patients are hyper-responsive to the TLR9 
agonist CpGB DNA, producing increased levels of TNF, IL6 and IL1ȕ following stimulation 
in vitro [21]. Furthermore, ENL derived skin biopsies exhibit abnormally high levels of 
TLR9 expression on various cell types including B-lymphocytes, monocytes and 
plasmacytoid dentritic cells (pDCs) [21]. Importantly, TLR7/TLR9 induced type-1 interferon 
production can drive systemic autoimmune disease with symptoms similar to those found in 
ENL, such as in skin lesions seen in SLE [22]. Thus, it is reasonable to suppose that ENL 
symptoms may arise from excessive TLR signalling in response to M. Leprae infection, and 
therefore, that the inhibitory effect of IMiDs on TLR induced cytokine and type-1 interferon 
production might potentially contribute to the efficacy of these compounds in the treatment of 
ENL. However, additional studies are warranted to validate this hypothesis. Furthermore, the 
effect of IMiDs on these same signalling pathways varies widely according to the cell type 
under investigation. For instance, lenalidomide treatment augmented type-1 interferon 
production in in vitro cell lines derived from a subset of B cell lymphoma; activated B-cell 
like (ABC) diffuse large B cell lymphoma (DLBCL)[23]. 
Thalidomide and in particular, its derivatives lenalidomide and pomalidomide, are known for 
their co-stimulatory effect on T-cell activation [6, 24]. Specifically, the stimulation of CD3 or 
PMA/Ionomycin activated human T-cells (both CD4+ and CD8+) with IMiDs has been 
reported to up-regulate TCR induced TNFα, ILβ and IFNȖ production in vitro [24-27]. 
Another study, the production of IL2, which has essential functions in promoting regulatory 
T-cell (Treg) differentiation, survival and function,[28] was suggested to underlie 
thalidomide efficacy in ENL following observations of enhanced Il2 production by patient 
derived PBMC, stimulated ex vivo with PMA and Ionomycine [29]. Indeed, IL2 has an 
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essential role in maintaining immune homeostasis as illustrated by the phenotype of Il2-/- 
mice, which spontaneously develop Colitis accompanied by unrestrained T-cell proliferation 
[30, 31]. The possibility; that thalidomide promotes Treg expansion via the up-regulation of 
IL2, remains to be clearly demonstrated. However, at least one study has noted an increase in 
gene expression of the Treg marker FOXP3 in PBMC isolated from ENL patients undergoing 
thalidomide treatment [29]. Moreover, analyses of PBMC derived from multiple myeloma 
and MDS del(5q) patients undergoing treatment with pomalidomide and lenalidomide, 
respectively, revealed an increase in Treg frequency as a proportion of total CD4+ T-cells 
following treatment onset [32, 33]. 
The in vitro observations of the immune-suppressive and co-stimulatory effects of 
thalidomide in monocytes and T-cells, respectively, are in principle, capable of explaining the 
efficacy of thalidomide in ENL. However, at present, both hypotheses lack sufficient 
experimental support. In particular, observations of serum cytokine levels in patients 
undergoing thalidomide treatment for ENL are inconsistent. A study of 20 Nepalese ENL 
patients concluded that disease resolution was accompanied by an increase in serum levels of 
TNFα and IL1β [29]. Furthermore, T-cells isolated from these patients and stimulated ex vivo 
(PMA/ Ionomycin) exhibited increased production of IL2, IL4 and IFN-Ȗ [29]. Based on 
these data we might conclude that the co-stimulatory property of thalidomide might be 
critical to resolving ENL symptoms. However, a separate study of 9 ENL patients from 
Mexico reported a decrease in serum TNFα and IFNȖ in response to thalidomide treatment 
that also correlated with reduced severity of disease symptoms [34]. Further clinical studies 
are required to understand whether the in vitro observations of thalidomide’s immune-
suppressive and co-stimulatory activity are relevant to its therapeutic effect in ENL. 
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Thalidomide in the Treatment of  Autoimmune Diseases 
While thalidomide’s anti-inflammatory properties are best characterised in the context of 
ENL, numerous case reports and small-scale studies suggest that thalidomide and its 
derivatives may be effective in the treatment of  diseases such as Rhuematoid Arthritis, 
Ulcerative Colitis, Crohn’s disease, (see Box 1) and dermatological complications 
associated with Behcet’s disease and SLE [14, 35, 36]. For the most part, however, these 
studies are not supported by large-scale controlled clinical trials. Consequently, while 
thalidomide exhibits potential in the treatment of autoimmune disease, it has so far failed to 
gain widespread acceptance as a treatment for immunological disorders other than ENL (Box 
2). 
Box 1. Clinicians corner 
 The use of thalidomide requires strict monitoring and patient compliance. Although 
reports indicate that lenalidomide and pomalidomide fail to induce teratogenicity in 
zebrafish and chick models of development,[37, 38] these compounds bind Cereblon 
and should therefore be considered teratogenic in humans [27, 39]. Thalidomide 
derivatives should therefore be used cautiously. 
 Thalidomide is likely to prove effective in IBD (both Ulcerative Colitis and Crohn’s 
disease)[35, 36], however, opinions differ over whether the side effect profile can be 
considered tolerable. Adverse events requiring suspension of treatment are 
experienced in approximately 20% of patients undergoing long term treatment [35]. 
Specifically, peripheral neuropathy (20-26% of patients), a neurological condition 
described as a ‘pins and needles’ sensation (tingling in hands and feet) can result in 
permanent neurological damage if treatment is not suspended. Furthermore, the 
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sedative effects of thalidomide (32-60% of patients) are sufficiently problematic such 
that existing first line treatments-such as 5-aminosalicyclic acid compounds- may be 
preferable [35, 36]. Nevertheless, thalidomide might be considered in patients 
refractory to existing treatments. Further studies are warranted to study the 
applicability of thalidomide derivatives for the treatment of IBD. 
 Thalidomide derivatives may also be considered suitable for dermatological 
complications associated with Behcet’s disease and SLE. For instance, lenalidomide 
is reported to be well tolerated and effective in cutaneous lupus erythmatosus [40, 41]. 
 
 
Box 2. Expanding the clinical potential of IMiDs 
IMiDs are the only class of drugs to initiate the proteosomal degradation of therapeutic 
targets by binding to an E3 ubiquitin ligase complex. Ligand activated ubiquitin ligases have 
been previously described; the aryl hydrocarbon receptor (Ahr) performs an analogous role to 
Cereblon in the CUL4B ubiquitin ligase complex. In this case, the binding of Ahr Ligands 
initiates recruitment and degradation of the estrogen receptor (ERα)[42]. Another example is 
the binding of Auxin, a plant growth hormone, to the TIR1 ubiquitin ligase, resulting in the 
degradation of the Aux/IAA family of transcriptional repressors [43]. The authors of this 
study noted the implications of their findings; that small molecules might be designed to 
promote protein-protein interactions with ubiquitin ligases [43]. The recent development of 
molecules that can effectively re-program CUL4ACRBN to degrade specific proteins promises 
to greatly expand the therapeutic potential of IMiDs. 
Proteolysis Targeting Chimera (PROTAC) 
Trends in Molecular Medicine 
11 
 
The targeting of a desired protein is made possible by the non-specific,  promiscuous nature 
of CUL4ACRBN. Proteins that come within a given range, as defined by the rotation of 
CUL4A around the DDB1/Cereblon substrate adaptor, are targeted for ubiquitination [44]. 
This has enormous implications for the design of IMiD based therapeutics; IMiDs based 
molecules can be designed to bring disease causing proteins into the effective range of 
CUL4ACRBN. Two groups have independently demonstrated the potential for this approach. 
Both studies combined IMiDs with chemical inhibitors of BRD4, a transcriptional regulator 
and therapeutic target in various types of cancer. The resultant compound effectively induced 
the Cereblon mediated degradation of BRD4 in Burkitts lymphoma cell lines while 
overcoming the problem of  acquired resistance seen with standard BRD4 inhibitors [45].  A 
similar compound proved effective in the treatment of murine leukemia in vivo [46]. This sort 
of IMiD based hybrid molecule, referred to as Proteolysis targeting chimera (PROTACs), 
have not yet been applied to the treatment of inflammatory and autoimmune diseases, but 
hold great potential. 
 
Molecular Mechanisms in IMiD Therapy 
Past studies have therefore described putative mechanisms that may potentially explain the 
properties of IMiDs in the treatment of ENL and potentially, in autoimmune diseases such as 
IBD and SLE. Now, the identification of Cereblon as a receptor for thalidomide has provided 
an opportunity to consider the molecular aspects of putative IMiD therapy in these diseases.  
Cereblon: The Thalidomide Receptor 
Using innovative IMiD coated beads, Cereblon was identified as a direct target of 
thalidomide, pomalidomide and lenalidomide [8, 27]. Cereblon, which shares homology to 
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the yeast protein Lon (N-terminal domain of the ATP –dependent protease La),[47] was first 
reported as the causative factor of a rare form of  inherited cognitive disorder (Autosomal 
Recessive Nonsyndromic Mental Retardation (ARNSMR)) based on genetic linkage analysis 
of an affected family [48]. Shortly thereafter, a mass spectroscopy based proteomic screen 
identified Cereblon as a putative component of the CUL4A//DDB1/RBX1 E3 ubiquitin ligase 
complex [7]. Cereblon is now also known to co-immunoprecipitate with the related ubiquitin 
ligase CUL4B [38, 49]. Added to this, proteomic screens have identified a large number of 
additional putative substrate adaptors, termed CUL4A associated factors (DCAFs),that are 
thought to function interchangeably with Cereblon in these complexes [7, 50]. Thus, there is 
potential for significant complexity, the importance of which remains poorly understood in 
relation to IMiD properties.  
The ubiquitin ligase function of Cereblon has since been experimentally verified with studies 
indicating that under physiological conditions CUL4ACRBN has important functions in 
maintaining metabolic homeostasis. For instance, degradation of metabolic enzyme 
Glutamate Synthetase (GS), which occurs in hepatic cell lines when glutamine concentrations 
are high,[51] was shown to be dependent on Cereblon in the Hep3B cell line [52]. Pull-down 
experiments in HEK293T cells further revealed that following treatment with glutamine, 
acetylation of two tandem lysine residues (K11, K14) in GS resulted in its recruitment to 
CUL4ACRBN and subsequent degradation via the ubiquitin proteasome pathway [52]. 
Although the in vivo relevance of these observations was not addressed, Crbn-/- mice are 
reported to be highly susceptible to weight gain when fed a high fat diet [53]. Evidence 
therefore suggests that CUL4ACRBN may be a physiologically relevant regulator of glutamine 
homeostasis (Box 3). These findings suggest that diet may be an important consideration for 
patients underoing IMiD therapy, although this remains to be investigated. 
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Box 3. Cereblon and the immune system. 
Only a handful of studies have investigated Cereblon function in the immune system. Using 
the CRISPR-Cas9 system to generate Cereblon deficient mice for the study of TLR 
responses, one study documented a small, albeit significant increase in TLR-induced TNFα, 
IFN-ȕ,  IL1βp40 and IL6 production in Cereblon deficient macrophages [18]. These 
observations are consistent with other findings showing that Crbn-/- mice exhibit a slightly 
increased susceptibility to endotoxic shock [54]. In this study, Cereblon knockdown (siRNA) 
in the THP-1 cell line was seen to augment LPS induced NFkB activation [54].  Furthermore, 
over-expression assays in HEK293T cells suggest a putative role for Cereblon in the 
regulation of  TRAF6 ubiquitination, although  further experiments using physiological 
systems are required to validate this point [54]. 
In our view, the contribution of Cereblon to regulating innate immune signaling pathways, 
and macrophage function, is quite small. A recent study suggests that Cereblon may have a 
more important role in shaping adaptive immunity. T-cells isolated from Cereblon deficient 
mice exhibit increased cytokine production in response to TCR activation [55]. Furthermore, 
T-cell specific deletion of Cereblon increases disease severity in Experimental Autoimmune 
Encephalomyelitis (EAE), a Th17 mediated murine model of Multiple Sclerosis involving 
central nervous system (CNS) inflammation [55]. While these findings may suggest a role for 
Cereblon in regulating T-cell activation, similar observations have been reported for CD147-/- 
mice, which exhibit increased susceptibility to EAE and enhanced Th17 cell differentiation in 
vitro [56]. The phenotype of Crbn-/- mice may therefore reflect a loss of Cereblon chaperone 
function in CD147 maturation [38]. Further investigation is required to determine whether 
Cereblon has a meaningful role in immune regulation. 
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Interestingly, the GS conjugated acetylation motif binds to Cereblon at the same location as 
IMiDs; an N-terminal hydrophobic pocket (Figure 2) [52, 57]. Thus, mutation of Tyrosine 
and Tryptophan residues at position 384 and 386 (human Cereblon), respectively, to Alanine 
(CRBNYW/AA), which is reported to abolish IMiD binding,[8] also prevented GS-Cereblon 
protein interactions [52]. We might therefore expect that thalidomide should compete with 
GS for Cereblon binding, however, for reasons that remain unclear, this appears not to be the 
case [52]. Further studies are thus required to understand how IMiD binding might affect the 
physiological function of Cereblon and whether this influences disease outcomes in 
conditions where IMiDs are used frequently, such as Multiple Myeloma and MDS del(5q). 
CUL4ACRBN Mediated Degradation of Ikaros and Aiolos Relieves Transcriptional 
Repression of the Il2 Promoter 
Proteomic and biochemical analyses have determined that, following IMiD binding, the 
ubiquitin ligase function of Cereblon is redirected to target proteins that would not ordinarily 
be subject to CUL4ACRBN regulation. IMiD binding to Cereblon results in the recruitment of 
target proteins, termed neo-substrates (to distinguish them from physiological substrates like 
GS), resulting in their ubiquitin mediated proteasomal degradation [58-62]. Mass-
spectrometry based proteomic studies have identified neo-substrates including the 
transcription factors Ikaros Family Zinc Finger Protein 1 and 3 (IKZF1 and IKZF3), also 
referred to as Ikaros and Aiolos, and the Casein kinase 1α (CK1α)[59-62]. The IMiD induced 
degradation of  neo-substrates is at least one contributing factor to IMiD efficacy in the 
treatment of Multiple Myeloma and MDS del5(q), with knockdown (shRNA) of IKZF1, 
IKZF3 and CK1α proving cytotoxic in in vitro cell lines derived from these malignancies (see 
box 4, box 5)[59-61, 63, 64], and reviewed elsewhere[63, 64]. 
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Box 4. IMiD therapy in cancer 
Multiple Myeloma 
Shortly after the identification of Cereblon as an IMiD receptor, the efficacy of IMiDs in 
Multiple Myeloma was investigated. Cereblon knockdown in Multiple Myeloma cell lines 
proved cytotoxic, however, stably transfected clones were resistant to IMiD treatment  [65]. 
Therefafter, two groups simultaneously reported the transcription factors Ikaros (IKZF1) and 
Alios (IKZF3) as targets of CUL4ACRBN. IMiD binding initiated the degradation of IKZF1 
and IKZF3 resulting in cytotoxicity in multiple myeloma cell lines in vitro [60, 61].  
MDS del(5q) 
Similar proteomic studies identified CK1α as a target in MDS del(5q)[59]. Lenalidomide 
stimulated the degradation of CK1α resulting in cytotoxicity in  MDS del(5q) cell lines[59]. 
A recent study revealed that IKZF1 degradation is also important to IMiD therapy in this 
condition. IKZF1 is a transcriptional suppressor of GRP68[66]. Following IKZF1 
degradation, GRP68 is up-regulated triggering a calcium-inducing signalling cascade and the 
activation of CAPN1, a calcium activated mediator of apoptosis [66]. MDS del(5q) cells are 
uniquely sensitive to this pathway owing to haplo-insufficiency for the CAPN1 inhibitor 
Caplastatin (CAST), which is encoded by a gene in the deleted 5q region [66]. 
Multiple Mechanisms to Explain the Effects of IMiD Therapy in Cancer? 
Neo-substrate (IKZF1, IKZF3, CK1α) degradation alone failed to explain why, for instance, 
proteasome inhibitors are effective in combination with IMiDs in Multiple Myeloma, despite 
the degradation of IKZF1 and IKZF3 occurring via the ubiquitin proteasome pathway [64]. 
These problems were solved with the identification of CD147 as a target of IMiDs. CD147 
knockdown is cytotoxic in both MDS del(5q) and multiple myeloma cell lines in vitro [38]. 
Together with the degradation of CUL4ACRBN neo-substrates, these mechanisms are 
suggested to combine to result in the observed IMiD effects during cancer treatment[64]. 
 
Box 5. Neo-substrate degradation influences functional differences in IMiD compounds. 
Target specificity varies among IMiD compounds. So for example, thalidomide, lenalidomide 
and pomalidomide can all effectively induce the degradation of  IKZF1 and IKZF3, while 
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only lenalidomide is effective in stimulating the degradation of CK1α in MDS del(5q) cell 
lines [59]. Protein interaction assays using Flurescence Resonance Energy Transfer (FRET) 
indicate that although thalidomide and pomalidomide are able to facilitate Cereblon-CK1α 
complex formation, this occurs at very low efficiency compared with lenalidomide [58]. 
Structural studies indicate that in the case of thalidomide and pomalidomide, the addition of  
a carbonyl group at position C3 (Highlighted on the chemical structure of lenalidomide 
below, Figure 1) clashes with the resolved crystal structure of Cereblon in complex with 
CK1α [58].   
Binding of the substrates themselves is remarkably similar. While IKZF1 and CK1α share no 
sequence homology, each shares a similar tertiary structure (ȕ-hairpin loop) that mediates 
binding to an identical region of Cereblon (aa351-400) (highlighted blue on the crystal 
structure of human Cereblon in complex with lenalidomide,[57] below)[58]. These studies 
provide a mechanistic explanation for the functional differences existing between IMiD 
compounds and why, for example, all three compounds are effective in Multiple Myeloma 
but only lenalidomide is effective in MDS del(5q)[59]. In contrast to selectivity in neo-
substrate degradation, thalidomide, lenalidomide and pomalidomide are reported to be 
equally effective at inducing the destabilisation of CD147/MCT-1[38]. Thus, neo-substrate 
specificity appears to be a primary source of diversity among IMiD compounds. 
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A handful of studies have investigated the relevance of this process in contributing to the 
anti-inflammatory properties of IMiDs. In particular, the degradation of IKZF1 and IKZF3 
has been suggested to influence IMiD-mediated costimulation and IL2 production in CD3 
activated T-cells by relieving transcriptional repression of the Il2 promoter [27, 62]. Indeed, 
treatment with pomalidomide or lenalidomide resulted in diminished protein levels of 
IKZF1/IKZF3 in primary human T-cells in vitro, [60, 62] which was rescued by Cereblon 
knockdown (siRNA) [62]. In support of this, the function of IKZF1 and IKZF3 as 
transcriptional repressors of Il2 has been well documented and ChIP-seq experiments have 
confirmed that both IKZF1 and IKZF3 bind up-stream of the Il2 promoter in mice [67, 68]. 
Specifically, CD4+ T-cells isolated from Ikzf1-/- mice, or from transgenic mice expressing a 
dominant negative mutant of IKZF1 (IK7DN) have been shown to produce increased 
amounts of IL2 following stimulation with anti-CD3 and anti-CD28 in vitro[68]. Meanwhile, 
IKZF3 can  promote T-helper 17 (Th17) cell differentiation via transcriptional repression of 
the  Il2 promoter.  Ikzf3 mRNA was markedly elevated in murine splenic CD4+ T-cells 
activated with CD3 and cultured under Th17 (but not Th1 or Th2) polarizing conditions 
(medium supplemented with cytokines that promote T-cell differentiation into an IL17 
producing subtype, for example IL6 with TGFȕ)  in vitro [67]. In this same study, CD4+ T-
cells derived from Ikzf3-/- mice produced increased amounts of IL2 and consequently, 
exhibited impaired Th17 differentiation relative to wild type controls [67]. Taken together, 
these studies suggest that IMiD-induced degradation of IKZF1 and IKZF3 might be 
responsible, at least in part, for IMiD-induced up-regulation of IL2 in activated T-cells. 
IMiD-induced augmentation of IL2 production, via the degradation of IKZF1 and IKZF3, 
may promote Treg survival,[69] suppress pathogenic Th17 cell expansion,[70] and thereby 
potentially contribute to the efficacy of IMiDs in the treatment of ENL. Further in vivo 
Trends in Molecular Medicine 
18 
 
studies are required to understand and validate the importance of this pathway in relation to 
the immune-suppressive effects of IMiDs. 
Cereblon: A Chaperone in CD147 Membrane Trafficking? 
The ubiquitin ligase function of CUL4ACRBN is by far the best studied aspect of IMiD 
signalling; however, other consequences to IMiD binding to Cereblon have been suggested. 
For example, sucrose gradient fractionation has revealed that Cereblon functions in at least 
two distinct protein complexes; IMiD complexed with CUL4A (~300KDa), and a lower 
molecular weight complex of Cereblon with the cell surface receptor CD147 and its co-
receptor Monocarboxylate Transporter-1 (MCT-1) (~120KDa) [38]. CD147 (Basigin, or 
Extracellular matrix metalloproteinase inducer (EMMPRIN)) is a trans-membrane 
glycoprotein with diverse functions and implicated the regulation of cell metabolism, 
invasion of erythrocytes by Plasmodium Falciparum,[71] metastasis, as well as T-cell 
maturation [72]. IMiD binding was shown to have an inhibitory effect on the Cereblon-
CD147 protein interaction resulting in the degradation of CD147 and MCT-1 in lenalidomide 
sensistive (MMS1, U266, AMO1, L363) but not lenalidomide resistant (KMS12BM, 
RPMI8226, JJN3, INA-6) Multiple Myeloma in vitro cell lines [38]. The degradation of 
CD147/MCT-1, and indeed also of IKZF1 and IKZF3, was observed to occur even in a cell 
line (MMS1) deficient for both CUL4A and CUL4B (shRNA). This unexpected observation, 
taken together with an accumulation of CD147/MCT-1 in the endoplasmic reticulum of IMiD 
treated cells, led the authors to suggest an alternative hypothesis; that the degradation of 
CD147/MCT-1 may reflect a distinct, chaperone-like function of Cereblon in the regulation 
of CD147/MCT1 maturation, trafficking and expression at the cell membrane [38]. This 
remains speculative however, and further studies are required to understand the precise 
mechanism whereby CD147/MCT-1 are degraded. Moreover, that IKZF1 and IKZF3 are 
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degraded in MMS1 cells deficient for both CUL4A and CUL4B is curious, and requires 
explanation. 
The authors of this study present evidence to support the role of this process in effecting 
thalidomide teratogenicity. For instance, in experiments using the zebrafish model of 
development, morpholino mediated knockdown of CD147 phenocopied thalidomide 
teratogencicity, manifesting in reduced head, fin and eye sizes, [38] which is consistent with 
observations of thalidomide treatment or Cereblon knockdown in this same model [8]. 
However, further investigation is required to understand whether this process is 
mechanistically and functionally relevant to IMiD therapy in ENL. It might be reasonable to 
suppose that, at least in some disorders, loss of CD147 expression could result in a T-cell 
mediated anti-inflammatory response. Transient blockade of CD147 using blocking 
monoclonal antibodies has been shown to be effective in murine EAE, primarily a Th17 
mediated disorder [73]. Moreover, human clinical trials have shown anti-CD147 blocking 
antibodies to be effective in the treatment of corticosteroid refractory Graft vs. Host Disease 
(GVHD) [74]. Further data may help elucidate whether Cereblon’s putative chaperone 
function in CD147 membrane trafficking is relevant in ENL (or other) diseases. 
IMiDs Disrupt a Cereblon-Rabex-5 Complex 
A recent study from our laboratory used in vitro over-expression/pull-down experiments in 
HEK293T cells to show that IMiD treatment could disrupt protein-protein interactions 
between Cereblon and an important regulator of immune homeostasis, the guanosine 
nucleotide exchange factor (GEF), Rabex-5[75, 76]. Mutation  of the IMiD binding site 
(CRBNYWAA) rescued these protein interactions confirming that this is a direct result of IMiD 
binding to Cereblon [75].  Notably, protein levels of Rabex-5 were unaffected by IMiD 
treatment or Cereblon overexpression, suggesting that Rabex-5 was not a substrate of 
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CUL4ACRBN [75].  Studies of Rabex-5 deficient mice revealed critical functions in the 
regulation of immune homeostasis in the skin; Rabex-5-/- mice rapidly succumb to a MYD88 
dependent inflammatory skin condition of unclear aetiology [76, 77].  Thus, we considered 
that Rabex-5 might be a putative effector of IMiD properties in inflammatory skin conditions 
such as ENL. Further investigation will be required to understand whether Rabex-5 function 
is influenced by the loss of interaction with Cereblon, and if so, whether this observation 
might help explain the acute activity of IMiDs in the treatment of inflammatory skin 
conditions (ENL, psoriasis), as opposed to other organs. 
Multiple Target Molecules Imply a Complex Mechanism of Action 
With many IMiD target molecules now identified (in addition to those discussed above; 
MEIS2, GSPT1[44, 78]), understanding which target molecules are of genuine relevance to 
IMiD therapy, particularly in complex immunological disorders such as ENL, is a 
considerable challenge. Many of the targets identified have important functions; either as 
transcription factors (IKZF1, IKZF3),[60, 61] kinases (CK1α),[59] cell surface receptors 
(CD147/MCT-1),[38] or ubiquitin ligases (Rabex-5),[75] raising the prospect of 
downstream/secondary targets, the identity and significance of which is poorly understood. 
Indeed, this list is not exhaustive and we expect that many other such proteins are likely to be 
reported in future studies.  
Added to this, much of the work has been performed in in vitro cancer cell lines and therefore, 
at least at present, the relevance of these processes to IMiD efficacy in ENL is at present 
largely conjecture. How the myriad primary targets, in addition to putative secondary targets, 
synthesise to result in the therapeutic effects of IMiDs in the treatment of autoimmune and 
inflammatory disorders, will require the use of more sophisticated approaches, including 
global gene expression and bioinformatics platforms, and importantly, the development of 
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appropriate in vivo systems for IMiD research. It will be necessary for studies to move 
beyond a simplified, single target molecule approach, that has characterised the field to date. 
Future Directions in IMiD Research: Humanized Mice 
The studies outlined above describe Cereblon mediated processes that may potentially 
explain some of the positive effects of  IMiD treatments in immunological disorders such as 
ENL, IBD and SLE. The challenge now is to understand the contribution of Cereblon to 
mediating the anti-inflammatory properties of IMiDs in vivo. This is currently hampered by 
the inability to use murine models of disease.  
Indeed, murine resistance to IMiD properties has been widely documented. Moreover,  
thalidomide administration induces birth defects, which are evident in chick and rabbit 
models of development, but fail to manifest in rodents [79]. Similarly, pomalidomide induced 
up-regulation of IL2 production is observed in human, but not murine PBMC (CD3 activated) 
in vitro [57]. Murine resistance to IMiDs used in anti-cancer treatments has also been noted 
[59]. Remarkably, these observations are explained by a single amino acid difference 
between human and mouse Cereblon. The substitution of Valine for Isoleucine at a position 
adjacent to the IMiD binding site (391, 387 in murine and human Cereblon respectively) 
prevents the degradation of IKZF1, IKZF3 and CK1α in murine cell lines [59]. For instance, 
over-expression of murine CereblonI391V enables lenalidomide induced degradation of CK1α 
in the murine leukemia cell line Ba/F3 [59]. Therefore, at least in vitro, IMiD responses can 
be ‘humanised’to a certain degree, by the smallest of changes. We expect that in coming 
years, the development and in vivo analysis of humanized CRBNI391V mice will be the subject 
of intense effort. 
Concluding Remarks 
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For many, thalidomide remains and will always be synonymous with tragedy. Images of 
thalidomide induced birth defects remain burned into the collective memory and it is with this 
in mind, and with great sensitivity, that we approach the subject of thalidomide’s more 
positive attributes. Perhaps, it may be said that recent decades have seen thalidomide undergo 
some degree of atonement. Research inspired, at least in part, by the observation of 
thalidomide’s anti-inflammatory properties and in particular the seminal report of 
thalidomide’s inhibitory effect on Toll-like receptor induced TNFα production,[15] has 
resulted in the development of thalidomide derivatives that have borne great impact on the 
treatment of a few cancers including Multiple Myeloma and MDS del(5q) [6, 63]. Today, 
lenalidomide (Revlimid®) is widely used to treat many of these malignancies. 
The use of IMiDs in the treatment of immunological disorders is clearly a much smaller 
market. However, in our view, it holds great potential. In particular, the use of IMiDs in 
autoimmune diseases such as IBD and SLE is, at least in part, hampered by the absence of 
data on IMiD efficacy in these conditions. Concerns over teratogenicity will no doubt 
continue to weigh heavily in the minds of medical practitioners, particularly given the 
prevalence of such diseases in individuals of reproductive age. However, thalidomide might 
be considered as an alternative in patients who prove refractory to existing treatments, and in 
our view, this makes understanding the anti-inflammatory properties of IMiDs an important 
topic for future research. The identification of Cereblon as an IMiD receptor has markedly 
enhanced our understanding; going forward, the anticipated development of humanised 
Cereblon mice might enable the in vivo characterisation of IMiD properties in murine models 
of autoimmune disease. Are the co-stimulatory or immune suppressive properties of 
thalidomide critical to its efficacy in these diseases? Just how important is Cereblon to these 
properties? (see outstanding questions box) Answers to these questions might, in turn, inform 
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clinical studies and ultimately, help expand the use of IMiDs in the treatment of 
immunological disorders.  
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Glossary 
Acute Myloid Leukemia 
Aggressive cancer affecting the myeloid lineage of hematopoietic cells. 
 
Anergic 
A t-cell is said to be anergic when it fails to respond to its cognate antigen. 
 
Apremilast 
Next generation IMiD with potent anti-inflammatory activity. 
 
ARNSMR 
Rare and relatively mild inherited cognitive disorder. 
 
B Streptococcus 
Gram negative strain of extracellular bacteria. 
 
Behcet’s disease 
Complex inflammatory disorder affecting mucosal surfaces. 
 
Chaperone 
Assists with correct folding/maturation of another protein. 
 
ChIP-seq 
Technique to demonstrate transcription factor binding. Immuno-precipitation of TF bound 
chromatin followed by sequence analysis.  
 
Clofazimine 
Antibiotic effective against mycobacteria. 
 
CpGB DNA 
DNA motif abundant in bacterial DNA. 
 
Cullin4A (CUL4A) 
Central scaffold protein in modular E3 ubiquitin ligase complex. 
 
CUL4ACRBN 
Modular E3 ubiqutin ligase. CUL4ACRBN denotes the Cereblon containing CUL4A complex. 
 
CRBNYWAA 
Mutation that eliminates IMiD binding. Y384/W386 to Alanine. 
 
Crohn’s disease  
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Inflammation affecting the upper digestive tract and terminal ileum. 
 
Enantiomer 
Mirror image chemical isoforms. 
 
Erythema Nodosum Leprosum 
Inflammatory reaction associated with Leprosy. Also referred to as a type-2 lepra reaction. 
 
Flourescence Resonance Energy Transfer (FRET) 
Flourescence based in vitro protein interaction assay. Proximity is measured by excitation at a 
particular wavelength. 
 
Glutarimide 
Derivative of Glutamic acid. 
 
Guanosine Nucleotide Exchange Factor (GEF) 
An activating enzyme that catalyses the transfer of GTP to GTPases. 
Graft vs. Host Disease 
Complication of organ transplantation, whereby the (host) immune system attacks the 
transplanted organ (graft). 
 
Hansen’s Disease 
Also known as Leprosy, an infectious disease resulting from infection with a species of 
Mycobacteria.  
 
Hepatocellular Carcinoma 
Cancer of the Liver often caused by viral infection. 
 
Inflammatory Bowel Disease (IBD) 
Inflammation of the digestive tract. There are two principal catagories; Crohn’s disease and 
Ulcerative Colitis. 
 
Lenalidomide 
Chemical derivative of thalidomide known for its use in the treatment of Multiple Myeloma 
and MDS del(5q). 
 
Lepramatous Leprosy 
Characterised by robust infection and weak antigen specific immune responses. 
 
Lipopolysaccharide 
Membrane component of gram negative bacteria. 
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Mantle Cell Lymphoma 
Subset of Non-Hodgkin Lymphoma (cancer affecting the lymphoid system). 
 
MDS del(5q) 
Subset of Myelodysplastic syndrome. A deletion in chromosome 5 results in 
haploinsufficiency. 
 
Morpholino 
An RNA binding oligo that blocks protein synthesis by binding to cognate mRNA. 
 
Multiple Myeloma 
B-cell malignancy characterised by excessive immunoglobulin production. 
Mycobacteria 
Gram positive strain of intracellular bacteria. 
 
Mycobacterium Leprae  
Gram positive intracellular bacterium .  
 
Mycobacterium Tuberculosis 
Gram positive intracellular bacterium. Infection mostly occurs in the respiratory system. 
 
Myelin Sheath 
Protective layer that enables neuron conductivity. 
 
Myelodysplastic Syndrome (MDS) 
Heterogenous group of hematopoietic cancers. 
 
Peripheral Nervous System (PNS) 
The nervous system excluding the brain and spinal cord. 
 
Phocomelia 
Abnormally short limb outgrowth. 
 
Plasmodium Falciparum 
Mosquito born parasite responsible for malaria. 
 
Pomalidomide 
Differs from lenalidomide with the addition of a carbonyl group on the pthalimide ring. 
 
Psoriasis 
Autoimmune disease affecting the skin. 
 
Pthalimide 
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Derivative of pthalic anhydride. 
 
Rab5 
GTPase. Considered the engine of early to late endosomal maturation. 
 
Rabex-5 
GEF thought to regulate Rab5 activation. Functions in intracellular transport and negatively 
regulates numerous signalling pathways. 
 
Racemic 
Composite mixture of enantiomers/isoforms. 
 
Rheumatoid Arthritis 
Autoimmune disease resulting in joint inflammation and damage to the surrounding bone and 
cartilage. 
 
Schwann cell 
Responsible for the synthesis of Myelin, essential for neuron function. 
 
Systemic Lupus Erythmatosus (SLE) 
Type-1 interferon driven multi-organ autoimmune disease characterised by autoantibody 
production. 
 
T-Helper 1 
Characterised by IFNȖ production. Promote macrophage function and the clearance of 
intracellular bacteria. 
 
T-Helper 17 (Th17) 
Pro-inflammatory T-cell subset characterised by high levels of IL17 production. 
 
The Thalidomide Trust 
UK based charity. 
 
Toll-like receptor 
A family of receptors that recognises pathogen derived proteins or nucleic acids and initiates 
a pro-inflammatory cytokine response. 
 
Tubercloid Leprosy 
Characterised by limited infection and strong antigen specific immune responses. 
 
Ulcerative Colitis 
Inflammation mostly affecting the large intestine.   
 
Trends in Molecular Medicine 
28 
 
Acknowledgements 
D.M. and T.K. conceived the article. D.M. wrote the manuscript. This work is supported by 
The Kishimoto Foundation. 
References 
1 Evans, H. (2014) Thalidomide: how men who blighted lives of thousands evaded justice. The 
Guardian  
2 Fletcher, M. (2016) Thalidomide 50 years on: 'Justice has never been done and it burns away'. The 
Telegraph  
3 Vargesson, N. (2015) Thalidomide-induced teratogenesis: history and mechanisms. Birth defects 
research. Part C, Embryo today : reviews 105, 140-156 
4 Dove, F. (2011) What's happened to thalidomide babies? BBC  
5 Sheskin, J. (1965) THALIDOMIDE IN THE TREATMENT OF LEPRA REACTIONS. Clinical pharmacology 
and therapeutics 6, 303-306 
6 Bartlett, J.B., et al. (2004) The evolution of thalidomide and its IMiD derivatives as anticancer 
agents. Nature reviews. Cancer 4, 314-322 
7 Angers, S., et al. (2006) Molecular architecture and assembly of the DDB1-CUL4A ubiquitin ligase 
machinery. Nature 443, 590-593 
8 Ito, T., et al. (2010) Identification of a primary target of thalidomide teratogenicity. Science (New 
York, N.Y.) 327, 1345-1350 
9 Masaki, T., et al. (2013) Reprogramming adult Schwann cells to stem cell-like cells by leprosy bacilli 
promotes dissemination of infection. Cell 152, 51-67 
10 Quiroga, M.F., et al. (2004) Activation of signaling lymphocytic activation molecule triggers a 
signaling cascade that enhances Th1 responses in human intracellular infection. Journal of 
immunology (Baltimore, Md. : 1950) 173, 4120-4129 
11 Teo, S., et al. (2002) Thalidomide in the treatment of leprosy. Microbes and infection 4, 1193-
1202 
12 Rodrigues, L.C. and Lockwood, D. (2011) Leprosy now: epidemiology, progress, challenges, and 
research gaps. The Lancet. Infectious diseases 11, 464-470 
ϭϯ Craǁford, C.L. ;ϮϬϭ6Ϳ CoŵŵeŶt oŶ ͞DNA “eŶsiŶg ǀia TLR-9 Constitutes a Major Innate Immunity 
Pathǁay Actiǀated duriŶg Erytheŵa Nodosuŵ Leprosuŵ͟. The Journal of Immunology 197, 4183-
4184 
14 Franks, M.E., et al. (2004) Thalidomide. Lancet (London, England) 363, 1802-1811 
15 Sampaio, E.P., et al. (1991) Thalidomide selectively inhibits tumor necrosis factor alpha 
production by stimulated human monocytes. The Journal of experimental medicine 173, 699-703 
16 Moreira, A.L., et al. (1993) Thalidomide exerts its inhibitory action on tumor necrosis factor alpha 
by enhancing mRNA degradation. The Journal of experimental medicine 177, 1675-1680 
17 Moller, D.R., et al. (1997) Inhibition of IL-12 production by thalidomide. Journal of immunology 
(Baltimore, Md. : 1950) 159, 5157-5161 
18 Millrine, D., et al. (2016) Immunomodulatory drugs inhibit TLR4-induced type-1 interferon 
production independently of Cereblon via suppression of the TRIF/IRF3 pathway. International 
immunology 28, 307-315 
19 Bafica, A., et al. (2005) TLR9 regulates Th1 responses and cooperates with TLR2 in mediating 
optimal resistance to Mycobacterium tuberculosis. The Journal of experimental medicine 202, 1715-
1724 
20 Mancuso, G., et al. (2009) Bacterial recognition by TLR7 in the lysosomes of conventional 
dendritic cells. Nature immunology 10, 587-594 
Trends in Molecular Medicine 
29 
 
21 Dias, A.A., et al. (2016) DNA Sensing via TLR-9 Constitutes a Major Innate Immunity Pathway 
Activated during Erythema Nodosum Leprosum.   
22 Marshak-Rothstein, A. (2006) Toll-like receptors in systemic autoimmune disease. Nature reviews. 
Immunology 6, 823-835 
23 Yang, Y., et al. (2012) Exploiting synthetic lethality for the therapy of ABC diffuse large B cell 
lymphoma. Cancer cell 21, 723-737 
24 LeBlanc, R., et al. (2004) Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. 
Blood 103, 1787-1790 
25 Payvandi, F., et al. (2005) Immunomodulatory drugs (IMiDs) increase the production of IL-2 from 
stimulated T cells by increasing PKC-theta activation and enhancing the DNA-binding activity of AP-1 
but not NF-kappaB, OCT-1, or NF-AT. Journal of interferon & cytokine research : the official journal of 
the International Society for Interferon and Cytokine Research 25, 604-616 
26 Xu, Y., et al. (2009) Immunomodulatory drugs reorganize cytoskeleton by modulating Rho 
GTPases. Blood 114, 338-345 
27 Lopez-Girona, A., et al. (2012) Cereblon is a direct protein target for immunomodulatory and 
antiproliferative activities of lenalidomide and pomalidomide. Leukemia 26, 2326-2335 
28 Boyman, O. and Sprent, J. (2012) The role of interleukin-2 during homeostasis and activation of 
the immune system. Nature reviews. Immunology 12, 180-190 
29 Haslett, P.A., et al. (2005) Effective treatment of erythema nodosum leprosum with thalidomide 
is associated with immune stimulation. The Journal of infectious diseases 192, 2045-2053 
30 Sadlack, B., et al. (1993) Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. 
Cell 75, 253-261 
31 Littman, D.R. and Rudensky, A.Y. (2010) Th17 and regulatory T cells in mediating and restraining 
inflammation. Cell 140, 845-858 
32 Balaian, E., et al. (2016) Selective expansion of regulatory T cells during lenalidomide treatment of 
myelodysplastic syndrome with isolated deletion 5q. Annals of hematology 95, 1805-1810 
33 Sehgal, K., et al. (2015) Clinical and pharmacodynamic analysis of pomalidomide dosing strategies 
in myeloma: impact of immune activation and cereblon targets. Blood 125, 4042-4051 
34 Partida-Sanchez, S., et al. (1998) IgG antibody subclasses, tumor necrosis factor and IFN-gamma 
levels in patients with type II lepra reaction on thalidomide treatment. International archives of 
allergy and immunology 116, 60-66 
35 Yang, C., et al. (2015) Systematic review: thalidomide and thalidomide analogues for treatment of 
inflammatory bowel disease. Alimentary pharmacology & therapeutics 41, 1079-1093 
36 Diamanti, A., et al. (2015) The clinical implications of thalidomide in inflammatory bowel diseases. 
Expert review of clinical immunology 11, 699-708 
37 Mahony, C., et al. (2013) Pomalidomide is nonteratogenic in chicken and zebrafish embryos and 
nonneurotoxic in vitro. Proceedings of the National Academy of Sciences of the United States of 
America 110, 12703-12708 
38 Eichner, R., et al. (2016) Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to 
exert antitumor activity and teratogenicity. Nature medicine 22, 735-743 
39 Zeldis, J.B., et al. (2013) Pomalidomide is teratogenic in rats and rabbits and can be neurotoxic in 
humans. Proceedings of the National Academy of Sciences of the United States of America 110, 
E4819 
40 Kindle, S.A., et al. (2016) Lenalidomide treatment of cutaneous lupus erythematosus: the Mayo 
Clinic experience. International journal of dermatology 55, e431-439 
41 Wu, E.Y., et al. (2016) Lenalidomide for refractory cutaneous manifestations of pediatric systemic 
lupus erythematosus. Lupus  
42 Ohtake, F., et al. (2007) Dioxin receptor is a ligand-dependent E3 ubiquitin ligase. Nature 446, 
562-566 
Trends in Molecular Medicine 
30 
 
43 Tan, X., et al. (2007) Mechanism of auxin perception by the TIR1 ubiquitin ligase. Nature 446, 640-
645 
44 Fischer, E.S., et al. (2014) Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with 
thalidomide. Nature 512, 49-53 
45 Lu, J., et al. (2015) Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4. 
Chemistry & biology 22, 755-763 
46 Winter, G.E., et al. (2015) DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo 
target protein degradation. Science (New York, N.Y.) 348, 1376-1381 
47 Kataoka, K., et al. (2016) Mitochondrial cereblon functions as a Lon-type protease. Scientific 
reports 6, 29986 
48 Higgins, J.J., et al. (2004) A mutation in a novel ATP-dependent Lon protease gene in a kindred 
with mild mental retardation. Neurology 63, 1927-1931 
49 Zhu, Y.X., et al. (2014) Identification of cereblon-binding proteins and relationship with response 
and survival after IMiDs in multiple myeloma. Blood 124, 536-545 
50 Lee, J. and Zhou, P. (2007) DCAFs, the missing link of the CUL4-DDB1 ubiquitin ligase. Molecular 
cell 26, 775-780 
51 Arad, G., et al. (1976) Glutamine-stimulated modification and degradation of glutamine 
synthetase in hepatoma tissue culture cells. Cell 8, 95-101 
52 Nguyen, T.V., et al. (2016) Glutamine Triggers Acetylation-Dependent Degradation of Glutamine 
Synthetase via the Thalidomide Receptor Cereblon. Molecular cell 61, 809-820 
53 Lee, K.M., et al. (2013) Disruption of the cereblon gene enhances hepatic AMPK activity and 
prevents high-fat diet-induced obesity and insulin resistance in mice. Diabetes 62, 1855-1864 
54 Min, Y., et al. (2016) Cereblon negatively regulates TLR4 signaling through the attenuation of 
ubiquitination of TRAF6. Cell death & disease 7, e2313 
55 Kang, J.A., et al. (2016) Epigenetic regulation of Kcna3-encoding Kv1.3 potassium channel by 
cereblon contributes to regulation of CD4+ T-cell activation. Proceedings of the National Academy of 
Sciences of the United States of America 113, 8771-8776 
56 Maeda, K., et al. (2015) CD147/basigin limits lupus nephritis and Th17 cell differentiation in mice 
by inhibiting the interleukin-6/STAT-3 pathway. Arthritis & rheumatology (Hoboken, N.J.) 67, 2185-
2195 
57 Chamberlain, P.P., et al. (2014) Structure of the human Cereblon-DDB1-lenalidomide complex 
reveals basis for responsiveness to thalidomide analogs. Nature structural & molecular biology 21, 
803-809 
58 Petzold, G., et al. (2016) Structural basis of lenalidomide-induced CK1alpha degradation by the 
CRL4(CRBN) ubiquitin ligase. Nature 532, 127-130 
59 Kronke, J., et al. (2015) Lenalidomide induces ubiquitination and degradation of CK1alpha in 
del(5q) MDS. Nature 523, 183-188 
60 Kronke, J., et al. (2013) Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple 
Myeloma Cells. Science (New York, N.Y.)  
61 Lu, G., et al. (2013) The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent 
Destruction of Ikaros Proteins. Science (New York, N.Y.)  
62 Gandhi, A.K., et al. (2014) Immunomodulatory agents lenalidomide and pomalidomide co-
stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the 
E3 ubiquitin ligase complex CRL4(CRBN.). British journal of haematology 164, 811-821 
63 Stewart, A.K. (2014) Medicine. How thalidomide works against cancer. Science (New York, N.Y.) 
343, 256-257 
64 Bergsagel, P.L. and Chesi, M. (2016) Promiscuous mechanisms underlie the antitumor effects of 
thalidomide analogs.  22, 706-707 
65 Zhu, Y.X., et al. (2011) Cereblon expression is required for the antimyeloma activity of 
lenalidomide and pomalidomide. Blood 118, 4771-4779 
Trends in Molecular Medicine 
31 
 
66 Fang, J., et al. (2016) A calcium- and calpain-dependent pathway determines the response to 
lenalidomide in myelodysplastic syndromes.  22, 727-734 
67 Quintana, F.J., et al. (2012) Aiolos promotes TH17 differentiation by directly silencing Il2 
expression. Nature immunology 13, 770-777 
68 Thomas, R.M., et al. (2007) Ikaros enforces the costimulatory requirement for IL2 gene expression 
and is required for anergy induction in CD4+ T lymphocytes. Journal of immunology (Baltimore, Md. : 
1950) 179, 7305-7315 
69 Sakaguchi, S., et al. (2010) FOXP3+ regulatory T cells in the human immune system. Nature 
reviews. Immunology 10, 490-500 
70 Laurence, A., et al. (2007) Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. 
Immunity 26, 371-381 
71 Crosnier, C., et al. (2011) Basigin is a receptor essential for erythrocyte invasion by Plasmodium 
falciparum. Nature 480, 534-537 
72 Hahn, J.N., et al. (2015) The role of EMMPRIN in T cell biology and immunological diseases. 
Journal of leukocyte biology 98, 33-48 
73 Agrawal, S.M., et al. (2012) A novel anti-EMMPRIN function-blocking antibody reduces T cell 
proliferation and neurotoxicity: relevance to multiple sclerosis. Journal of neuroinflammation 9, 64 
74 Deeg, H.J., et al. (2001) Treatment of steroid-refractory acute graft-versus-host disease with anti-
CD147 monoclonal antibody ABX-CBL. Blood 98, 2052-2058 
75 Millrine, D., et al. (2016) Rabex-5 is a lenalidomide target molecule that negatively regulates TLR-
induced type 1 IFN production. Proceedings of the National Academy of Sciences of the United States 
of America  
76 Tam, S.Y., et al. (2004) RabGEF1 is a negative regulator of mast cell activation and skin 
inflammation. Nature immunology 5, 844-852 
77 Marichal, T., et al. (2016) Guanine nucleotide exchange factor RABGEF1 regulates keratinocyte-
intrinsic signaling to maintain skin homeostasis. The Journal of clinical investigation 126, 4497-4515 
78 Matyskiela, M.E., et al. (2016) A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) 
ubiquitin ligase. Nature 535, 252-257 
79 Fratta, I.D., et al. (1965) TERATOGENIC EFFECTS OF THALIDOMIDE IN RABBITS, RATS, HAMSTERS, 
AND MICE. Toxicology and applied pharmacology 7, 268-286 
80 Hoglund, P., et al. (1998) A double-blind study of the sedative effects of the thalidomide 
enantiomers in humans. Journal of pharmacokinetics and biopharmaceutics 26, 363-383 
81 Muller, G.W., et al. (1996) Structural modifications of thalidomide produce analogs with 
enhanced tumor necrosis factor inhibitory activity. Journal of medicinal chemistry 39, 3238-3240 
82 Schafer, P.H., et al. (2014) Apremilast is a selective PDE4 inhibitor with regulatory effects on 
innate immunity. Cellular signalling 26, 2016-2029 
83 Hartmann, M.D., et al. (2014) Thalidomide mimics uridine binding to an aromatic cage in cereblon. 
Journal of structural biology 188, 225-232 
84 Mattera, R. and Bonifacino, J.S. (2008) Ubiquitin binding and conjugation regulate the 
recruitment of Rabex-5 to early endosomes. The EMBO journal 27, 2484-2494 
 
 
 
 
 
Trends in Molecular Medicine 
32 
 
Figure Legends 
Figure 1. Chemical Characteristics of Thalidomide Derivatives. Thalidomide is a fusion 
of pthalimide and glutarimide (bottom left) ring moieties and is produced as a mixture of 
two enantiomers (mirror image chemical isoforms: (S) and (R)). Structural and experimental 
observations show that only the S enantiomer is Cereblon binding [27, 44]. The R enantiomer 
is suggested to mediate the sedative properties of thalidomide [80] . However, purification is 
meaningless as both isoforms are rapidly and spontaneously inter-converted in fluids[14]. 
Inter-conversion of enantiomers means that thalidomide is produced and administered as a 
racemic mixture. The glutarimide ring is responsible for Cereblon binding [27, 44, 57], while 
the pthalimide ring is implicated in the suppressive effect of thalidomide on 
lipopolysaccharide induced TNFα production [81]. Chemical modifications to the pthalimide 
ring result in the derivatives lenalidomide and pomalidomide, which are more effective 
inhibitors of this pathway [6]. Apremilast may also be regarded as a thalidomide related 
compound as it shares the pthalimide ring; however, this compound does not bind Cereblon 
[82]. 
Figure 2. The Crystal Structure of Lenalidomide in Complex with Human Cereblon. 
Lenalidomide (green) is embedded in a pocket composed of three Tryptophan residues [57]; 
W380, W386 and W400 (red). The glutarimide portion of the molecule is embedded in 
Cereblon while the pthalimide moiety is exposed. Lenalidomide is secured by three hydrogen 
bonds (dotted yellow lines). Each IMiD binds with essentially the same affinity and 
conformation, however, in the case of thalidomide and pomalidomide, two hydrogen bonds 
extending from the glutarimide ring are sufficient to anchor the molecule (the hydrogen bond 
extending from the pthalimide ring is not present) [27, 57]. Similar results have been obtained 
for the crystal structure of IMiDs in complex with Gallus Gallus Cereblon [44]. Mutation of 
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Y384 (yellow) and W386 (red, labelled) to Alanine (CRBNYWAA) mostly eliminates IMiD 
binding [8, 27]. Endogenous molecules are also able to bind this pocket. For instance, the 
tandem acetylation motif on Glutamate Synthetase [52]. The ribonucleoside Uridine is also 
suggested to be a putative endogenous ligand [83]. Image generated using Pymol 
(Scrhodinger) with pre-existing pdb file (4tz4, reported [57]). 
Key Figure, Figure 3. Molecular Processes Underlying IMiD Properties. (1) IMiD 
binding inhibits a chaperone-like function of Cereblon in promoting the trafficking and 
maturation of CD147. In the absence of Cereblon or following IMiD treatment, CD147 (blue) 
and its co-receptor MCT-1 (purple) fail to translocate into the Golgi apparatus and instead 
accumulate at the endoplasmic reticulum (red cross). CD147 therefore fails to mature into its 
high glycosylated form and does not express at the cell surface [38]. This process may 
explain why Cereblon fails to interact with Rabex-5, an important regulator of immune 
homeostasis that localises to a variety of intracellular vesicles [75, 76, 84]. (2) Cereblon also 
functions in a completely separate complex with the CUL4A E3 ubiquitin ligase (CUL4A 
serves as a scaffold. Complex also includes DDB1; a flexible linker connecting Cereblon, and 
RBX1; possesses E3ubiquitin ligase activity)[7]. Here, Cereblon functions as a substrate 
adaptor; binding to Cereblon brings substrates into proximity with CUL4A enabling their 
K48 linked ubiqutination (dashed black arrow) and subsequent degradation via the ubiquitin 
proteasome pathway (not shown) [44, 57, 58, 63]. IMiD binding changes the surface of 
Cereblon to facilitate protein-protein interactions with IKZF1, IKZF3, CK1α and perhaps 
other, yet to be identified proteins [59-61]. This process may occur in the nucleus,[64] 
however, CUL4ACRBN cannot bind active IKZF1/IKZF3; the structure of IKZF1/IKZF3 when 
bound to cognate DNA sequences interferes with Cereblon binding [58]. Lenalidomide is 
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shown as a representative example. Lenalidomide, and not thalidomide or pomalidomide is 
able to induce the degradation of CK1α. 
 
Figure 1 (Box 5) The Crystal structure of human Cereblon in complex with lenalidomide. 
Image generated using Pymol (Scrhodinger) with pre-existing pdb file (4tz4, reported [57]). 
Region in blue shows the substrate binding region of Cereblon. The critical C3 is marked on 
the chemical structure of lenalidomide. 
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